Cash/Burn From SEC Filing For Period: 

Q2 2020

ITCI

Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Paul Greengard’s Nobel Prize-winning research that uncovered how therapies affect the inner-working of cells in the body. We leverage this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. We celebrate science, welcome curiosity, expect collaboration and demand integrity and respect in all we do create and deliver.

Cash

$407.8M

Burn Rate

$186.6M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Caplyta (Lumateperone)

Schizophrenia

Quarterly Sales

October 29, 2020 (Est.)

Lumateperone

Bipolar Depression

Submit sNDA

Late 2020 (Est.)

ITI021-105

Heart Failure

Phase 2

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon